Study record · Somatropin (recombinant human growth hormone)
Recombinant GH replacement in adult growth-hormone deficiency
GH replacement improved several deficiency-related outcomes including body composition in the diagnosed GHD population.
Key result
GH replacement improved several deficiency-related outcomes including body composition in the diagnosed GHD population.
Study details
Study designRandomized double-blind placebo-controlled multicenter trial
PopulationAdults with confirmed growth-hormone deficiency
Sample size166
RouteSubcutaneous
Regimen / exposure0.0125 mg/kg/day initially, titrated up to 0.025 mg/kg/day as tolerated
Duration12 months
ComparatorPlacebo
Primary endpoint / questionBody composition, lipids, exercise capacity and quality of life
Safety resultClass adverse effects are dose-related and require clinical monitoring.
Key limitationsEvidence applies to diagnosed GH deficiency and regulated somatropin, not anti-ageing/bodybuilding use in otherwise healthy adults.
Registry / identifierPMID 15126520